Ovarian tumor marker HE4 is differently expressed during the phases of the menstrual cycle in healthy young women

被引:59
作者
Anastasi, Emanuela [1 ,3 ]
Granato, Teresa [2 ]
Marchei, Giulia Giovanna [3 ]
Viggiani, Valentina [3 ]
Colaprisca, Barbara [3 ]
Comploj, Sara [3 ]
Reale, Maria Gabriella [3 ]
Frati, Luigi [3 ]
Midulla, Cecilia [3 ]
机构
[1] Univ Sapienza, Dept Oncol, Lab Tumor Markers, I-00161 Rome, Italy
[2] CNR, CNR IBPM, Rome, Italy
[3] Univ Sapienza, Dept Oncol, I-00161 Rome, Italy
关键词
HE4; Hormonal cycle; Age; CA; 125; BIOMARKERS; CANCER; SERUM; CA-125; DIAGNOSIS; EVOLUTION; TISSUES; LOCUS;
D O I
10.1007/s13277-010-0049-1
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
The objective of the present study was to investigate in healthy young women the fluctuations in serum concentration of human epididymal secretory protein human epididymis-specific protein 4 (HE4) and CA125 during the phases of the menstrual cycle and the correlation between HE4 and CA125 values and age. Forty women with regular menstrual cycles were included in the study. Pelvic and transvaginal ultrasound were performed in order to exclude ovarian pathologies. Blood samples were collected at follicular (FP), ovulatory (OP), and luteal (LP) phases of the hormonal cycle. The values of HE4 (expressed as picomoles per liter) observed were (mean +/- SEM) 39.1 +/- 1.1 (FP), 45.3 +/- 1.19 (OP), and 42.0 +/- 1.3 (LP). The difference between FP and OP was statistically significant (p = 0.0002). By contrast, serum CA125 levels (expressed as units per milliliter) were 14.35 +/- 0.66 (FP), 13.15 +/- 0.54 (OP), and 13.70 +/- 0.54 (LP), respectively. The levels of HE4 observed in serum samples of women below 35 years were 37.5 +/- 1.28 in the FP, 46.6 +/- 1.4 in the OP, and 42.8 +/- 1.49 in the LP. In this group, a statistically significant difference was observed in the FP compared with the OP (p < 0.0001), whereas no statistically significant difference was observed during the different hormonal phases in the group of women over 35. In conclusion, the correct interpretation of laboratory data is essential to define a threshold of normality, and for what concerns HE4 levels, the menstrual cycle phase-dependent variability appears indicated in the interpretation of the results.
引用
收藏
页码:411 / 415
页数:5
相关论文
共 25 条
[1]   HE4: a new potential early biomarker for the recurrence of ovarian cancer [J].
Anastasi, Emanuela ;
Marchei, Giulia Giovanna ;
Viggiani, Valentina ;
Gennarini, Giuseppina ;
Frati, Luigi ;
Reale, Maria Gabriella .
TUMOR BIOLOGY, 2010, 31 (02) :113-119
[2]   The putative ovarian tumour marker gene HE4 (WFDC2), is expressed in normal tissues and undergoes complex alternative splicing to yield multiple protein isoforms [J].
Bingle, L ;
Singleton, V ;
Bingle, CD .
ONCOGENE, 2002, 21 (17) :2768-2773
[3]   Biomarkers in cancer epidemiology: an integrative approach [J].
Boffetta, Paolo .
CARCINOGENESIS, 2010, 31 (01) :121-126
[4]   Fluctuations in CA 125 and CA 15-3 serum concentrations during spontaneous ovulatory cycles [J].
Bon, GG ;
Kenemans, P ;
Dekker, JJ ;
Hompes, PG ;
Verstraeten, RA ;
van Kamp, GJ ;
Schoemaker, J .
HUMAN REPRODUCTION, 1999, 14 (02) :566-570
[5]  
CHEN DX, 1988, OBSTET GYNECOL, V72, P23
[6]   The evolution of a genetic locus encoding small serine proteinase inhibitors [J].
Clauss, A ;
Lilja, H ;
Lundwall, Å .
BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS, 2005, 333 (02) :383-389
[7]   A locus on human chromosome 20 contains several genes expressing protease inhibitor domains with homology to whey acidic protein [J].
Clauss, A ;
Lilja, H ;
Lundwall, Å .
BIOCHEMICAL JOURNAL, 2002, 368 (01) :233-242
[8]   Serum and pleural fluid biomarkers for mesothelioma [J].
Creaney, Jenette ;
Robinson, Bruce W. S. .
CURRENT OPINION IN PULMONARY MEDICINE, 2009, 15 (04) :366-370
[9]   Menstrual cycle dependent variability for serum tumor markers CEA, AFP, CA 19-9, CA 125 and CA 15-3 in healthy women [J].
Erbagci, AB ;
Yilmaz, N ;
Kutlar, I .
DISEASE MARKERS, 1999, 15 (04) :259-267
[10]   Biomarkers in Early Cancer Drug Development: Limited Utility [J].
Glassman, R. H. ;
Ratain, M. J. .
CLINICAL PHARMACOLOGY & THERAPEUTICS, 2009, 85 (02) :134-135